Entropy Technologies LP Buys 33,274 Shares of Stryker Corporation $SYK

Entropy Technologies LP increased its stake in shares of Stryker Corporation (NYSE:SYK) by 381.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 42,005 shares of the medical technology company’s stock after acquiring an additional 33,274 shares during the quarter. Stryker accounts for 0.8% of Entropy Technologies LP’s portfolio, making the stock its 15th biggest position. Entropy Technologies LP’s holdings in Stryker were worth $14,763,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Godfrey Financial Associates Inc. bought a new stake in Stryker during the fourth quarter worth $26,000. United Financial Planning Group LLC bought a new stake in Stryker during the third quarter worth $27,000. Atlas Capital Advisors Inc. bought a new position in Stryker in the 4th quarter valued at $27,000. DJE Kapital AG bought a new position in Stryker in the 4th quarter valued at $28,000. Finally, Strive Asset Management LLC bought a new position in Stryker in the 3rd quarter valued at $30,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In other news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. This represents a 28.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 323,264 shares of company stock valued at $100,659,489 in the last 90 days. Insiders own 4.60% of the company’s stock.

Stryker Stock Up 2.1%

Shares of NYSE SYK opened at $312.14 on Friday. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The business’s fifty day moving average price is $316.40 and its 200-day moving average price is $343.97. The stock has a market capitalization of $119.66 billion, a PE ratio of 36.13, a P/E/G ratio of 1.97 and a beta of 0.78.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the prior year, the company earned $2.84 EPS. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts anticipate that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is currently 40.74%.

Analyst Ratings Changes

SYK has been the subject of a number of recent analyst reports. Canaccord Genuity Group reduced their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. UBS Group reduced their price objective on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Truist Financial restated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Weiss Ratings downgraded Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Finally, JPMorgan Chase & Co. reduced their price objective on Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $395.33.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.